Conexeu Sciences (CNXU) and the Wound Care Reset

The Wound Care Problem Hiding in Plain Sight

Wounds that won’t heal are one of the most expensive problems in American medicine, and one of the least discussed.

A landmark Value in Health study combed through Medicare data and found that nearly 15% of beneficiaries, about 8.2 million people, had at least one type of wound or wound infection. Surgical wounds were the costliest category, followed by diabetic foot ulcers.³ Those are the patients behind numbers like a split-open surgical incision, a crater left after Mohs skin-cancer surgery, or a burn that has to be rebuilt layer by layer.

The gold rush, and the crackdown

Here’s a story most retail investors missed. Medicare Part B spending on skin substitutes ran about $1.5 billion in 2022 and $4.4 billion in 2023⁸, then topped $10 billion in 2024.¹ Patient volume didn’t grow anywhere near that fast. Researchers tied much of the surge to a pricing loophole that let some sellers profit on the gap between Medicare’s payment and their actual costs.¹

Since January 1, 2026, Medicare pays a flat national rate of $127.14 per square centimeter for most skin substitutes.⁹ CMS projected savings of about $19.6 billion in 2026 while rewarding “products with the most clinical evidence of success.”² For later years, it intends to set payment by FDA category: full premarket approval, 510(k) clearance, or lightly regulated tissue products.⁹

In my opinion, that’s the most important regulatory shift in wound care in a decade. The easy-money era built on billing angles is ending. The next era should favor products with a real FDA pathway and real data behind them. That’s the lane Conexeu is aiming for, though it has no human data yet.

Opening Summary

Between 2019 and 2024, Medicare’s spending on skin substitutes, the sheets of processed tissue laid over hard-to-heal wounds, went from about $250 million to more than $10 billion. That’s a 40-fold jump in five years.¹ Then Washington slammed the door, cutting payments by nearly 90% and promising to reward the products with the strongest clinical evidence.²

That reset matters for investors, because the underlying problem hasn’t gone anywhere. A study of Medicare data put annual spending on wounds somewhere between $28.1 billion and $96.8 billion.³ In Conexeu’s view, the basic toolkit for deep, irregular wounds still relies largely on pre-formed sheets, powders and grafts that don’t fully fit the shape of the hole. Laying a flat sheet over a tunneling wound is a bit like laying a rug over a pothole. The top looks covered. The hole underneath is still a hole.

Conexeu Sciences (NASDAQ: CNXU) is building a different answer. Its lead device candidate, Ten-Minute Tissue™, is designed to go in as a liquid, flow into gaps that sheets and powders may not fully reach, the company says, and set in about ten minutes into a scaffold designed to give the body’s own cells a framework to move into.⁴[*7][*9][*10] Ten-Minute Tissue™ is investigational and in preclinical development, according to the company’s October 6, 2026 release, and has not been cleared or approved by the FDA for any use.⁴

On October 6, 2026, the company said multiple scaled-up manufacturing batches met specification and its FDA 510(k) submission remains on track for the first quarter of 2027.⁴ The company’s statement is forward-looking. Its actual results may differ; see the cautionary language in its Form 10-Q for the quarter ended July 31, 2026 and its press release dated October 6, 2026.

Here’s the investment case, why the last few months matter, and what’s still unproven.

Key Figures

Full source citations are numbered inline and listed in the Sources section below.

Conexeu Sciences · Nasdaq: CNXUDownload CNXU Corporate PresentationDownload the Presentation →

What Just Happened, and Why It Matters

Over the past five months, Conexeu has put four building blocks in place. Each one maps to a specific piece of the investment case.

May 21, 2026: a Nasdaq listing. Conexeu began trading on Nasdaq through a direct listing.¹⁰

Why it matters: A development-stage device company needs access to capital to get through FDA testing and into manufacturing. A Nasdaq listing gives Conexeu access to public capital markets.

June 8: manufacturing transfer and FDA feedback. Conexeu said it had transferred standardized formulation methods to a contract manufacturer and was working toward its 510(k) submission¹¹, and said it had received FDA feedback through the agency’s Q-Submission process.⁴

Why it matters: Pre-submission feedback is the FDA telling a company what it wants to see before the formal filing. Incorporating it early lowers the risk of an expensive surprise later. In our view, few signals are more useful for a 510(k) thesis.

July 7: the platform evidence package. Conexeu completed its 12-month P.R.O.O.F. preclinical study, reporting that it met its objectives across facial, large-volume and injectable-performance benchmarks.¹²

Why it matters: P.R.O.O.F. targets aesthetics, not wound care. But Conexeu describes its platform as one platform⁴, though its staged pathway lists a separate human-collagen formulation for aesthetics⁶. P.R.O.O.F. targets aesthetics, not wound care; aesthetics would need its own, separate PMA pathway.

October 6: scaled-up batches meet spec, timeline reaffirmed. Conexeu said multiple scaled-up batches of CXU™ material met its predefined specifications and that its 510(k) submission remains on track for the first quarter of 2027. Work on biocompatibility, chemical characterization, sterilization, packaging and stability is running in parallel.⁴

Why it matters: Plenty of promising materials die at the factory, not the lab. Reproducible batches are the raw material for regulatory testing and, eventually, commercial supply. As CEO Miles Harrison put it, the company has “moved from process development to implementing a controlled manufacturing process.”⁴ Reaffirming the timeline after it slipped once before is in our view, a useful execution signal, though the date remains the company’s target.

An Incomplete Standard

Look at what’s on the market for deep and complex wounds today, and most formats share the same two weaknesses: they don’t fully fill irregular wound beds, and they can be slow to integrate with the patient’s own tissue.

Source: Conexeu’s characterization of current formats.⁶

Conexeu reviewed every device the FDA has cleared since 2020 under product code KGN, a family of collagen wound dressings and the code its lead candidate targets. By the company’s count, 28 of those 43 devices are sheets and 32 are essentially “collagen only.” Just 2 deliver a multi-component extracellular matrix, the natural mesh that holds tissue together. And none of the 43 offer a flowable, injectable, temperature-set scaffold.⁶ That’s the company’s own analysis of public FDA records and hasn’t been independently verified. But if it holds up, it describes an open space in the format, by the company’s count.

Format isn’t just convenience. In a 2022 mouse study, the group at a leading university behind Conexeu’s science compared its liquid scaffold with a commercially available injectable collagen product indicated for tunneling wounds. The study assessed integration, host-cell infiltration and foreign-body response for both materials.¹³ It’s one animal study. But it frames the right question: does the body treat a material as a building site, or as an intruder?

Ten-Minute Tissue™ is designed to fill the wound rather than cover it.

How It’s Supposed to Work

Ten-Minute Tissue™ is built on CXU™, a multi-component collagen-based ECM scaffold platform, a framework modeled on the natural mesh that holds tissue together, developed over more than a decade at a leading university.¹⁴ According to company filings and releases, it is designed to work in four steps:

1. Stored as a powder. It ships freeze-dried and shelf-stable without special cold storage, then is rehydrated before use.¹⁴
2. Applied as a liquid. At room temperature it stays fluid, so it can be flowed into deep, irregular and tunneling wounds, including through a fine needle.⁴
3. Sets in place. At body temperature it turns into a stable gel within about ten minutes, staying in close contact with the entire wound surface.⁴
4. Becomes a scaffold. It is designed so the patient’s own cells can move in and use it as a framework.[*9][*10]

Think of it as pouring concrete instead of laying a rug. The concrete takes the exact shape of the hole, then becomes something you can build on. Ten-Minute Tissue™ is a device candidate on the FDA’s 510(k) pathway.

In animal and lab studies, researchers looked at how well the body’s cells moved into the material[*9][*10], whether new blood vessels grew into it[*3][*6], how well it blended with the surrounding tissue[*10] and how much inflammation it caused.[*10] That work is published in peer-reviewed journals, including Tissue Engineering Part A in 2015¹⁵[*3], Advances in Wound Care in 2021¹⁶[*7], Experimental Dermatology in 2022¹⁷[*9] and Gels in 2022.¹³[*10] To its credit, the company says plainly that none of those studies tested CXU™ in the specific wound types it plans to target first.⁴

Conexeu owns its platform patents outright, with patents issued in the U.S., EU, Japan and Australia and pending in Canada, with no royalty or licensing obligations.⁴

The Regulatory Path

Conexeu is taking the FDA’s 510(k) route, where a company shows its device is “substantially equivalent” to one already legally sold in the U.S. The FDA’s goal is a decision within 90 days of active review, a clock that pauses while the company answers questions. That’s generally far shorter than premarket approval, which typically requires clinical trials that can take years.²¹

The first targets are the wounds where shape matters most: deep defects after Mohs skin-cancer surgery, surgical wounds that have split back open, burns, and wounds that tunnel beneath the skin.⁴ Current workstreams include preclinical wound-model studies to support equivalence to an identified predicate, biocompatibility, chemical characterization, sterilization, packaging and stability testing.⁴

Subject to clearance, wound care is meant to be Conexeu’s first commercial product and the foundation it plans to expand from into dental, veterinary, 3D bioprinting and, later, aesthetics, which would require its own, separate PMA pathway.⁶ The company describes wound care as the near-term, lower-cost route to first revenue.⁶

The Market: What Big Companies Pay for Better Wound Care

Large medtech companies rarely invent the next wound-care category. They buy it, and they pay up.

Conexeu has not announced any acquisition discussions; these deals are market context, not a prediction.

Conexeu Sciences (Nasdaq: CNXU): 10 Points to Weigh

1. The Problem Is Large and Costly

A Value in Health study of Medicare data estimated annual spending on wounds and wound infections at $28.1 billion to $96.8 billion, and found that nearly 15% of beneficiaries, about 8.2 million people, had at least one wound or wound infection.³ Surgical wounds were the costliest category.

2. Medicare Is Paying for Evidence

Since January 1, 2026, Medicare pays a flat national rate of $127.14 per square centimeter for most skin substitutes, and CMS says it intends to reward the products with the most clinical evidence and to set later payment by FDA category.^2,9 A cleared device with clinical data would be positioned for that world; Conexeu’s published science so far is preclinical.

3. The Hardest Wounds Are the Irregular Ones

Deep defects after Mohs skin-cancer surgery, surgical wounds that split back open, burns and wounds that tunnel beneath the skin are where shape matters most, and they are the company’s first targets.⁴ In Conexeu’s view, sheets, powders and grafts don’t fully fit those wound beds.⁶

4. The Company Counts Few Comparable Formats

Conexeu reviewed the devices the FDA has cleared under product code KGN and, by its count, none of 43 is a flowable, injectable, temperature-set scaffold.⁶ The analysis is the company’s own and has not been independently verified, and collagen flowables and gels are already on the market.

5. The Goal Is a Scaffold That Sets in Place

Ten-Minute Tissue™ is designed to go in as a liquid, set into a gel at body temperature in about ten minutes, and give the patient’s own cells a framework to populate.⁴[*7][*9][*10] It is investigational and has not been tested in people.

6. It Ships as a Powder

The material is designed to be stored freeze-dried, without special cold storage, and rehydrated before use,¹⁴ a practical point for clinics and supply chains if it reaches market.

7. The FDA Has Weighed In Early

Conexeu has received FDA feedback through the agency’s Q-Submission process and says it is incorporating it.⁴ Pre-submission feedback is the FDA telling a company what it wants to see before the formal filing.

8. Manufacturing Is Scaling

The company says multiple scaled-up batches met its predefined specifications, with biocompatibility, sterilization, packaging and stability work running in parallel.⁴ Plenty of promising materials stall at the factory; reproducible batches are what regulatory testing needs.

9. Buyers Have Paid for Wound Platforms

Solventum paid $725 million upfront for Acera Surgical in 2025, and Integra paid $300 million upfront for ACell in 2021.^7,18 Both bought businesses with products and sales already in place; Conexeu has neither yet.

10. Wound Care Is the First Test

Wound care is meant to be the company’s first product and the base for its other programs in dental, veterinary and 3D bioprinting; aesthetics would need its own, separate PMA pathway.⁶ The 510(k) submission is targeted for the first quarter of 2027.⁴ A clearance would be the platform’s first regulatory milestone; a delay would likely push back the programs built on it.

What’s Still Unproven, and Why It Still Matters

No preclinical device company comes without risk, and Conexeu is no exception. So far Ten-Minute Tissue™ has not been tested in people. Everything above comes from preclinical and animal-model research, and none of the cited studies tested it in the specific wound types the company is targeting first.⁴ A submission is not a clearance: the FDA may ask for more data or testing, or decide the device is not substantially equivalent to its identified predicate.⁴ And reimbursement is tighter than it was: Medicare’s flat skin-substitute rate caps what products in this space can earn per square centimeter, so Conexeu will need to show its product fits that box.⁹

Competition is real. Solventum, Integra, Smith & Nephew and others bring sales forces, hospital contracts and clinical data a startup lacks. The 0-of-43 format analysis is the company’s own review of public FDA records and has not been independently verified.⁶

The one thing to watch is the 510(k) submission in the first quarter of 2027, and the FDA questions that follow.⁴

The Bottom Line

Wound care has spent decades covering holes it couldn’t fill.

Conexeu’s wound-care program is the nearest-term, most advanced piece of its story. It has a predicate-based FDA pathway, pre-submission feedback in hand, manufacturing batches meeting spec, more than a decade of peer-reviewed preclinical science, and a submission date the company reaffirmed on October 6, 2026.⁴ It’s also the milestone every other part of the platform depends on. Whether it clears, and what follows, is for the FDA, and you, to judge.

None of that is a clinical result or a clearance yet. That’s what makes this a speculative position rather than a sure thing.

Here’s what I’d watch over the next 12 months:

1. The 510(k) submission in the first quarter of 2027, and any FDA questions that follow.
2. Progress toward commercial manufacturing and supplier agreements.
3. Any commercial or distribution partner in wound care, which would signal outside validation.

Read the SEC filings and the underlying press releases, and talk to a qualified financial advisor before deciding anything.

Conexeu Sciences · Nasdaq: CNXUDownload CNXU Corporate PresentationDownload the Presentation →